Vinorelbine Plus Paclitaxel in Treating Patients With Metastatic Prostate Cancer That Is Refractory to Hormone Therapy

Part of paid clinical trials in Washington D.C., District of Columbia.

Sponsor
James Ahlgren
Study ID
NCT00003622
Phase
PHASE2
Status
Withdrawn

Conditions

Eligibility Criteria

Sex
MALE
Age
18 Years - 120 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of vinorelbine plus paclitaxel in treating patients with metastatic prostate cancer that is refractory to hormone therapy.

Key Dates

Start date
Jan 31, 1999
Status verified
Jul 2017
Primary completion
May 31, 2008
Completion
Feb 22, 2017

Study Design

Enrollment
0 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: paclitaxel + vinorelbine

Locations (1)

FacilityCityStateZIPSite coordinators
George Washington University HospitalWashington D.C.District of Columbia20037-

Find similar trials in Washington D.C., DC

By condition
Prostate cancer
By specialty
OncologyProstate oncologyMen's healthUrology
By research site
George Washington University Hospital· Washington D.C., DC

Related Studies